| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| AUPHAurinia Pharmaceuticals Inc. | 1.96B | 14.87 | 378.37 | 33.97% | 29.28% | 21.28% | 2.25% | 0.21 |
| ARGXargenx SE | 50.33B | 813.24 | 63.63 | 78.6% | 23.34% | 15.14% | 0.01 | |
| INVAInnoviva, Inc. | 1.48B | 19.76 | 54.89 | 15.54% | 32.78% | 12.61% | 12.75% | 0.65 |
| GLPGGalapagos N.V. | 2.24B | 34.03 | 30.38 | 14.99% | -151.94% | -15.16% | 0.00 | |
| PTGXProtagonist Therapeutics, Inc. | 5.3B | 84.75 | 20.04 | 6.24% | 21.94% | 7.11% | 3.45% | 0.02 |
| ALMSAlumis Inc. Common Stock | 2.84B | 24.17 | -2.33 | -11.08% | -63.71% | 0.12 | ||
| PHATPhathom Pharmaceuticals, Inc. | 1.17B | 14.98 | -2.83 | 80.01% | -186.53% | |||
| ORKAOruka Therapeutics, Inc. | 1.57B | 32.50 | -6.51 | -22.44% | 0.00 |
| Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 948K | 394K | 444K | 2.02M | 1.64M | 2.37M | 1.88M | 0 | 225K | 400K |
| Revenue Growth % | -0.49% | -0.58% | 0.13% | 3.55% | -0.19% | 0.45% | -0.21% | -1% | - | 0.78% |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 703K | 1.46M | 3.79M | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | 0.43% | 0.62% | 2.01% | - | - | - |
| Gross Profit | 948K | 394K | 444K | 2.02M | 935K | 909K | -1.91M | 0 | 225K | 400K |
| Gross Margin % | 1% | 1% | 1% | 1% | 0.57% | 0.38% | -1.01% | - | 1% | 1% |
| Gross Profit Growth % | -0.49% | -0.58% | 0.13% | 3.55% | -0.54% | -0.03% | -3.1% | 1% | - | 0.78% |
| Operating Expenses | 10.84M | 14.67M | 14.67M | 17.81M | 14.94M | 32.02M | 27.79M | 29.34M | 16.86M | 19M |
| OpEx % of Revenue | 11.44% | 37.23% | 33.04% | 8.82% | 9.12% | 13.5% | 14.75% | - | 74.93% | 47.51% |
| Selling, General & Admin | 7.68M | 10.55M | 10.69M | 12.33M | 11.37M | 21.89M | 17.96M | 19.02M | 11.67M | 10.69M |
| SG&A % of Revenue | 8.11% | 26.78% | 24.07% | 6.11% | 6.94% | 9.23% | 9.53% | - | 51.88% | 26.73% |
| Research & Development | 3.16M | 4.12M | 3.99M | 5.47M | 3.57M | 9.99M | 9.83M | 10.33M | 5.18M | 8.31M |
| R&D % of Revenue | 3.33% | 10.45% | 8.98% | 2.71% | 2.18% | 4.21% | 5.22% | - | 23.04% | 20.78% |
| Other Operating Expenses | 21K | 25K | 19K | 16K | 0 | 143K | 0 | 0 | 0 | 0 |
| Operating Income | -9.89M | -14.27M | -14.23M | -15.79M | -14M | -31.11M | -29.7M | -29.34M | -16.63M | -18.6M |
| Operating Margin % | -10.44% | -36.23% | -32.04% | -7.82% | -8.55% | -13.12% | -15.76% | - | -73.93% | -46.51% |
| Operating Income Growth % | -0.48% | -0.44% | 0% | -0.11% | 0.11% | -1.22% | 0.05% | 0.01% | 0.43% | -0.12% |
| EBITDA | -8.95M | -12.6M | -12.52M | -14.04M | -11.76M | -28.7M | -25.91M | -27.96M | -15.38M | -17.48M |
| EBITDA Margin % | -9.44% | -31.97% | -28.19% | -6.96% | -7.18% | -12.1% | -13.75% | - | -68.37% | -43.69% |
| EBITDA Growth % | -0.42% | -0.41% | 0.01% | -0.12% | 0.16% | -1.44% | 0.1% | -0.08% | 0.45% | -0.14% |
| D&A (Non-Cash Add-back) | 940K | 1.68M | 1.71M | 1.75M | 2.24M | 2.41M | 3.79M | 1.38M | 1.25M | 1.13M |
| EBIT | -9.85M | -14.21M | -14.19M | -15.7M | -13.98M | -30.97M | -29.51M | -29.23M | -15.27M | -18.16M |
| Net Interest Income | -785K | -1.89M | -1.9M | -1.82M | -2.45M | -2.31M | 177K | 130K | 191K | 225K |
| Interest Income | 22K | 39K | 15K | 75K | 15K | 140K | 177K | 130K | 363K | 437K |
| Interest Expense | 807K | 1.93M | 1.92M | 1.9M | 2.47M | 2.45M | 0 | 0 | 172K | 212K |
| Other Income/Expense | -764K | -1.86M | -1.88M | -1.81M | -2.44M | 7.9M | 184K | 32K | 1.19M | 225K |
| Pretax Income | -10.66M | -14.53M | -16.11M | -17.6M | -16.44M | -23.21M | -29.51M | -29.31M | -15.44M | -18.38M |
| Pretax Margin % | -11.24% | -36.88% | -36.28% | -8.72% | -10.04% | -9.79% | -15.67% | - | -68.64% | -45.94% |
| Income Tax | -65K | 347K | 34K | -4K | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0.92% | 1% | 1% | 1% | 1% | 1% | 1.71% | 2.22% | 1.61% | 1% |
| Net Income | -9.76M | -14.53M | -16.11M | -17.59M | -16.44M | -23.21M | -50.39M | -65.01M | -24.91M | -18.38M |
| Net Margin % | -10.3% | -36.88% | -36.27% | -8.72% | -10.04% | -9.79% | -26.75% | - | -110.7% | -45.94% |
| Net Income Growth % | -0.47% | -0.49% | -0.11% | -0.09% | 0.07% | -0.41% | -1.17% | -0.29% | 0.62% | 0.26% |
| Net Income (Continuing) | -10.66M | -16.14M | -16.11M | -17.6M | -16.44M | -23.21M | -29.51M | -29.31M | -15.44M | -18.38M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | -20.79M | -35.7M | -9.46M | 0 |
| Minority Interest | 14.11M | 1K | -2K | -6K | -11K | -17K | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -600.00 | -20.38 | -18.94 | -35.25 | -40.26 | -60.00 | -58.49 | -23.94 | -6.50 | -1.75 |
| EPS Growth % | -0.33% | 0.97% | 0.07% | -0.86% | -0.14% | -0.49% | 0.03% | 0.59% | 0.73% | 0.73% |
| EPS (Basic) | -600.00 | -20.38 | -18.94 | -35.25 | -40.26 | -60.00 | -58.49 | -23.94 | -6.50 | -1.75 |
| Diluted Shares Outstanding | 647.78K | 712.88K | 850.48K | 499.07K | 469.79K | 391.24K | 872.1K | 1.23M | 3.83M | 10.5M |
| Basic Shares Outstanding | 647.78K | 712.88K | 850.48K | 499.07K | 469.79K | 391.24K | 872.1K | 1.23M | 3.83M | 10.5M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 23.91M | 8.57M | 16.29M | 4.81M | 61.75M | 104.6M | 45.07M | 26.26M | 15.67M | 9.72M |
| Cash & Short-Term Investments | 23.01M | 8.09M | 15.93M | 4.42M | 55.11M | 96.97M | 33.52M | 7.33M | 14.21M | 8.58M |
| Cash Only | 23.01M | 8.09M | 15.93M | 4.42M | 55.11M | 77.4M | 22.68M | 7.33M | 14.21M | 8.58M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 19.57M | 10.85M | 0 | 0 | 0 |
| Accounts Receivable | 606K | 175K | 75K | 97K | 5.62M | 5.53M | 6.1M | 204K | 713K | 105K |
| Days Sales Outstanding | 233.32 | 162.12 | 61.66 | 17.54 | 1.25K | 850.69 | 1.18K | - | 1.16K | 95.81 |
| Inventory | 22K | 26K | 0 | 0 | 798K | 27K | 3.9M | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | 414.32 | 6.74 | 375.49 | - | - | - |
| Other Current Assets | 0 | 0 | 276K | 0 | 0 | 0 | 0 | 18.73M | 749K | 1.03M |
| Total Non-Current Assets | 27.69M | 27.44M | 26.8M | 25.78M | 32.44M | 42.37M | 54.34M | 14.95M | 13.06M | 13.46M |
| Property, Plant & Equipment | 25.57M | 25.59M | 25.15M | 24.38M | 31.27M | 34.74M | 41.76M | 7.55M | 6.37M | 5.28M |
| Fixed Asset Turnover | 0.04x | 0.02x | 0.02x | 0.08x | 0.05x | 0.07x | 0.05x | - | 0.04x | 0.08x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 2.09M | 1.82M | 1.62M | 1.37M | 1.14M | 952K | 4.85M | 5.39M | 5.37M | 6.85M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 7.63M | 1.96M | 0 | 1.31M |
| Other Non-Current Assets | 28K | 26K | 26K | 24K | 24K | 6.68M | 7.73M | 50K | 1.32M | 26K |
| Total Assets | 51.6M | 36.01M | 43.08M | 30.59M | 94.19M | 146.97M | 99.41M | 41.21M | 28.73M | 23.18M |
| Asset Turnover | 0.02x | 0.01x | 0.01x | 0.07x | 0.02x | 0.02x | 0.02x | - | 0.01x | 0.02x |
| Asset Growth % | 3.13% | -0.3% | 0.2% | -0.29% | 2.08% | 0.56% | -0.32% | -0.59% | -0.3% | -0.19% |
| Total Current Liabilities | 2.29M | 2.01M | 2.04M | 3.46M | 5.24M | 6.64M | 30.44M | 21.58M | 3.84M | 6.11M |
| Accounts Payable | 677K | 332K | 790K | 1M | 1.76M | 2.25M | 4.26M | 1.85M | 358K | 2.19M |
| Days Payables Outstanding | - | - | - | - | 913.28 | 562.73 | 410.54 | - | - | - |
| Short-Term Debt | 170K | 183K | 197K | 0 | 261K | 600K | 22.16M | 13.6M | 218K | 766K |
| Deferred Revenue (Current) | 24K | 157K | 471K | 1000K | 1000K | 423K | 100K | 0 | 200K | 1000K |
| Other Current Liabilities | 895K | 717K | 718K | 0 | 0 | 0 | 754K | 2.52M | 761K | 876K |
| Current Ratio | 10.43x | 4.26x | 8.00x | 1.39x | 11.79x | 15.74x | 1.48x | 1.22x | 4.08x | 1.59x |
| Quick Ratio | 10.43x | 4.25x | 8.00x | 1.39x | 11.64x | 15.74x | 1.35x | 1.22x | 4.08x | 1.59x |
| Cash Conversion Cycle | - | - | - | - | 754.26 | 294.7 | 1.15K | - | - | - |
| Total Non-Current Liabilities | 25.27M | 25.08M | 24.88M | 24.67M | 32.35M | 31.75M | 5.49M | 4.24M | 3.57M | 2.2M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 339K | 0 | 0 | 0 | 766K | 0 |
| Capital Lease Obligations | 25.27M | 25.08M | 24.88M | 24.67M | 32.01M | 31.75M | 3.51M | 3.48M | 2.74M | 2.2M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 1.97M | 768K | 63K | 0 |
| Total Liabilities | 27.56M | 27.09M | 26.92M | 28.13M | 37.58M | 38.4M | 35.92M | 25.83M | 7.41M | 8.3M |
| Total Debt | 25.43M | 25.27M | 25.08M | 24.88M | 32.91M | 32.72M | 25.77M | 17.07M | 4.46M | 3.51M |
| Net Debt | 2.42M | 17.18M | 9.15M | 20.46M | -22.2M | -44.68M | 3.09M | 9.75M | -9.75M | -5.07M |
| Debt / Equity | 1.06x | 2.83x | 1.55x | 10.13x | 0.58x | 0.30x | 0.41x | 1.11x | 0.21x | 0.24x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -12.26x | -7.40x | -7.43x | -8.31x | -5.68x | -12.68x | - | - | -96.71x | -87.75x |
| Total Equity | 24.04M | 8.91M | 16.16M | 2.46M | 56.61M | 108.57M | 63.48M | 15.38M | 21.32M | 14.88M |
| Equity Growth % | 1.14% | -0.63% | 0.81% | -0.85% | 22.04% | 0.92% | -0.42% | -0.76% | 0.39% | -0.3% |
| Book Value per Share | 37.12 | 12.51 | 19.01 | 4.92 | 120.49 | 277.50 | 72.80 | 12.56 | 5.57 | 1.42 |
| Total Shareholders' Equity | 9.94M | 8.91M | 16.17M | 2.46M | 56.62M | 108.58M | 63.48M | 15.38M | 21.32M | 14.88M |
| Common Stock | 89K | 89K | 16K | 20K | 140K | 9K | 9K | 20K | 9K | 19K |
| Retained Earnings | -57.59M | -72.12M | -88.23M | -105.82M | -150.42M | -173.63M | -223.93M | -288.94M | -313.85M | -332.22M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -29K | -29K | -30K | -31K | -33K | -63K | -213K | 0 | 0 | 0 |
| Minority Interest | 14.11M | 1K | -2K | -6K | -11K | -17K | 0 | 0 | 0 | 0 |
| Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -8.07M | -13.16M | -13.48M | -13.97M | -13.35M | -30.06M | -37.8M | -30.44M | -18.55M | -15.3M |
| Operating CF Margin % | -8.51% | -33.41% | -30.36% | -6.93% | -8.15% | -12.68% | -20.06% | - | -82.46% | -38.26% |
| Operating CF Growth % | -0.71% | -0.63% | -0.02% | -0.04% | 0.05% | -1.25% | -0.26% | 0.19% | 0.39% | 0.18% |
| Net Income | -10.66M | -16.14M | -16.11M | -17.6M | -16.44M | -23.21M | -29.51M | -65.01M | -24.91M | -18.38M |
| Depreciation & Amortization | 940K | 1.68M | 1.71M | 1.75M | 2.24M | 2.41M | 3.79M | 1.38M | 1.25M | 291K |
| Stock-Based Compensation | 1.25M | 1.01M | 770K | 241K | 388K | 1.59M | 0 | 4.39M | 2.04M | 1.53M |
| Deferred Taxes | 893K | 1.61M | 3K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -860K | -1.61M | 58K | 179K | 0 | 303K | -15.32M | 22.93M | 6.23M | 773K |
| Working Capital Changes | 367K | 290K | 88K | 1.45M | 470K | -11.15M | 3.24M | 5.87M | -3.17M | 479K |
| Change in Receivables | -39K | 309K | 39K | -22K | 22K | -10.74M | 4.21M | 6.1M | 0 | 0 |
| Change in Inventory | -22K | -4K | 26K | -96K | -798K | 772K | -3.87M | -1.01M | 0 | 0 |
| Change in Payables | -125K | -257K | 49K | 292K | 498K | 48K | 1.24M | -625K | -1.49M | 1.83M |
| Cash from Investing | -68K | -1.59M | -1.08M | -990K | -1.15M | -26.48M | -5.13M | 7.01M | 906K | 742K |
| Capital Expenditures | -68K | -1.59M | -1.08M | -990K | -1.08M | -4.92M | -11.63M | -5.74M | -210K | -16K |
| CapEx % of Revenue | 0.07% | 4.04% | 2.43% | 0.49% | 0.66% | 2.08% | 6.17% | - | 0.93% | 0.04% |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | -76K | -1.74M | 0 | 2.6M | 1.12M | 758K |
| Cash from Financing | 21.66M | -170K | 22.41M | 3.45M | 65.19M | 78.83M | -5.8M | 2.3M | 24.49M | 8.93M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | 16.01M | 0 | 0 | 0 | 4.29M | 890K | -50K | -22K | 197K | 0 |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -8.14M | -14.76M | -14.56M | -14.96M | -14.5M | -35.23M | -45.13M | -36.17M | -18.76M | -15.32M |
| FCF Margin % | -8.59% | -37.45% | -32.79% | -7.42% | -8.85% | -14.86% | -23.96% | - | -83.4% | -38.3% |
| FCF Growth % | -0.65% | -0.81% | 0.01% | -0.03% | 0.03% | -1.43% | -0.28% | 0.2% | 0.48% | 0.18% |
| FCF per Share | -12.57 | -20.70 | -17.12 | -29.99 | -30.86 | -90.04 | -51.75 | -29.53 | -4.90 | -1.46 |
| FCF Conversion (FCF/Net Income) | 0.83x | 0.91x | 0.84x | 0.79x | 0.81x | 1.30x | 0.75x | 0.47x | 0.74x | 0.83x |
| Interest Paid | 0 | 0 | 0 | 0 | 2.37M | 2.45M | 0 | 687K | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -55.36% | -88.18% | -128.43% | -188.96% | -55.66% | -28.1% | -58.58% | -164.86% | -135.71% | -101.52% |
| Return on Invested Capital (ROIC) | -52.62% | -40.74% | -41.52% | -49.1% | -36.64% | -47.48% | -34.14% | -48% | -67.98% | -130.51% |
| Gross Margin | 100% | 100% | 100% | 100% | 57.08% | 38.34% | -101.22% | - | 100% | 100% |
| Net Margin | -1029.96% | -3688.32% | -3627.25% | -871.8% | -1003.6% | -978.79% | -2674.68% | - | -11069.78% | -4594.25% |
| Debt / Equity | 1.06x | 2.83x | 1.55x | 10.13x | 0.58x | 0.30x | 0.41x | 1.11x | 0.21x | 0.24x |
| Interest Coverage | -12.26x | -7.40x | -7.43x | -8.31x | -5.68x | -12.68x | - | - | -96.71x | -87.75x |
| FCF Conversion | 0.83x | 0.91x | 0.84x | 0.79x | 0.81x | 1.30x | 0.75x | 0.47x | 0.74x | 0.83x |
| Revenue Growth | -48.78% | -58.44% | 12.69% | 354.5% | -18.83% | 44.75% | -20.54% | -100% | - | 77.78% |
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| Ibio Cdmo | - | - | - | 92K | 1.27M |
| Ibio Cdmo Growth | - | - | - | - | 1284.78% |
| Ibio Inc | 271K | - | 2.02M | 1.55M | 1.1M |
| Ibio Inc Growth | - | - | - | -23.39% | -28.98% |
| Grant | - | 44K | - | - | - |
| Grant Growth | - | - | - | - | - |
| iBio CDMO | 123K | - | - | - | - |
| iBio CDMO Growth | - | - | - | - | - |
iBio, Inc. (IBIO) reported $0.5M in revenue for fiscal year 2025. This represents a 61% decrease from $1.3M in 2012.
iBio, Inc. (IBIO) grew revenue by 77.8% over the past year. This is strong growth.
iBio, Inc. (IBIO) reported a net loss of $20.1M for fiscal year 2025.
iBio, Inc. (IBIO) has a return on equity (ROE) of -101.5%. Negative ROE indicates the company is unprofitable.
iBio, Inc. (IBIO) had negative free cash flow of $17.3M in fiscal year 2025, likely due to heavy capital investments.